Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
D000179:Acrylates / Q000494:pharmacology*; D000818:Animals; D001241:Aspirin / Q000494:pharmacology; D001792:Blood Platelets / Q000378:metabolism; D003327:Coronary Disease / Q000517:prevention & control*; D000242:Cyclic AMP / Q000097:blood; D016861:Cyclooxygenase Inhibitors; D004285:Dogs; D011464:Epoprostenol / Q000096:biosynthesis*; D005260:Female; D007052:Ibuprofen / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D008689:Methacrylates / Q000494:pharmacology*; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D010974:Platelet Aggregation / Q000187:drug effects; D011453:Prostaglandins / Q000096:biosynthesis*; D011463:Prostaglandins H / Q000378:metabolism; D013930:Thromboxane-A Synthase / Q000037:antagonists & inhibitors*
D000179:Acrylates; D016861:Cyclooxygenase Inhibitors; D008689:Methacrylates; D011453:Prostaglandins; D011463:Prostaglandins H; C031517:2-methyl-3-(4-(3-pyridinylmethyl)phenyl)-2-propenoic acid; D011464:Epoprostenol; D000242:Cyclic AMP; D010088:Oxidoreductases; D013930:Thromboxane-A Synthase; D001241:Aspirin; D007052:Ibuprofen; D007213:Indomethacin